{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:46:43Z","timestamp":1777420003858,"version":"3.51.4"},"reference-count":52,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2006,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To provide information for physicians and patients on which to base a decision as to whether to stop mandatory blood testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>Articles on drug-induced blood dyscrasias were identified by searches of MEDLINE (1966\u2014September 2005) and review of their bibliographies. Novartis was asked to provide additional data on clozapine, leukopenia, agranulocytosis, and suicidality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Data on the chance of clozapine-induced leukopenia and agranulocytosis were combined with data about possible fatality and compared with the risks associated with other medications and with life in general.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>The chance of clozapine-induced leukopenia or agranulocytosis decreases exponentially over time. In the US, the chance in the second 6 months of treatment is 0.70\/1000 patient-years and, after the first year, 0.39\/1000 patient-years. The case fatality rate of clozapine-induced agranulocytosis is estimated as 4.2\u201316%, depending on whether a granulocyte colony-stimulating factor is used. Nevertheless, treatment with clozapine reduces overall mortality, probably because it reduces suicidality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>After at least 6 months' treatment with clozapine, the mortality involved in stopping white blood cell monitoring is about the same as the mortality associated with other medications, such as mianserin or phenylbutazone, and with life in general (traffic or occupational accident). If the patient has been well informed and wishes to stop the monitoring, it is a medically justifiable option to do so and is preferable to stopping treatment with clozapine since this drug reduces overall mortality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1g396","type":"journal-article","created":{"date-parts":[[2006,3,6]],"date-time":"2006-03-06T20:39:39Z","timestamp":1141677579000},"page":"683-688","source":"Crossref","is-referenced-by-count":93,"title":["Risk of Clozapine-Associated Agranulocytosis and Mandatory White Blood Cell Monitoring"],"prefix":"10.1177","volume":"40","author":[{"given":"Peter FJ","family":"Schulte","sequence":"first","affiliation":[{"name":"Mental Health Services North\u2013Holland North, Department De Dijk, Kennemerstraatweg 464,1851 NG Heiloo, Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2006,4,1]]},"reference":[{"key":"bibr1-aph.1G396","volume-title":"Committee for Proprietary Medicinal Products (CMPC) summary information on referral opinion following arbitration pursuant to Article 30 of Council Directive 2001\/83\/EC for Leponex and associated names","author":"EMEA.","year":"2005"},{"key":"bibr2-aph.1G396","unstructured":"Prescribing information. Clozaril (clozapine). November 2004. www.fda.gov\/cder\/foi\/label\/2005\/019758s0541b1.pdf (accessed 2005 Sept 4)."},{"key":"bibr3-aph.1G396","unstructured":"FDA advisors back reduced monitoring for patients on clozapine. Reuters Health Information, June 16, 2003."},{"key":"bibr4-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199711000-00014"},{"key":"bibr5-aph.1G396","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200014050-00003"},{"key":"bibr6-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199307153290303"},{"key":"bibr7-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.175.6.576"},{"key":"bibr8-aph.1G396","unstructured":"Kumar V. Clozaril monitoring systems, registry data and analyses (United States, United Kingdom, & Australia), www.fda.gov\/ohrms\/dockets\/ac\/03\/slides\/3959S1_02_C-Novartis-Kumar.ppt (accessed 2005 Jul 1)."},{"key":"bibr9-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A417"},{"key":"bibr10-aph.1G396","first-page":"170","volume-title":"The drug etiology of agranulocytosis and aplastic anemia","author":"Kaufman DW","year":"1991"},{"key":"bibr11-aph.1G396","first-page":"226","volume-title":"The drug etiology of agranulocytosis and aplastic anemia","author":"Kaufman DW","year":"1991"},{"key":"bibr12-aph.1G396","first-page":"27","volume-title":"The drug etiology of agranulocytosis and aplastic anemia","author":"Heimpel H.","year":"1991"},{"key":"bibr13-aph.1G396","first-page":"287","volume":"28","author":"Hummer M","year":"1992","journal-title":"Psychopharmacol Bull"},{"key":"bibr14-aph.1G396","first-page":"117","volume-title":"Meyler's side effects of drugs","author":"Simpson GM","year":"1996","edition":"13"},{"key":"bibr15-aph.1G396","first-page":"35","volume":"22","author":"Lamarque V.","year":"1996","journal-title":"Encephale"},{"key":"bibr16-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1007\/BF00442573"},{"key":"bibr17-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1969.03160100052013"},{"key":"bibr18-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)93248-N"},{"key":"bibr19-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1007\/s002280000190"},{"key":"bibr20-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00773.x"},{"key":"bibr21-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1986.03380130077032"},{"key":"bibr22-aph.1G396","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bmj.297.6643.262","volume":"297","author":"Risk of agranulocytosis and aplastic anaemia in relation to antithyroid drugs.","year":"1988","journal-title":"BMJ"},{"key":"bibr23-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb00062.x"},{"key":"bibr24-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1996.tb01641.x"},{"key":"bibr25-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1007\/BF00442575"},{"key":"bibr26-aph.1G396","first-page":"401","volume":"55","author":"Gullion G","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"bibr27-aph.1G396","first-page":"139","volume":"55","author":"Gerson SL","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"bibr28-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb08042.x"},{"key":"bibr29-aph.1G396","first-page":"90","volume":"112","author":"Ban A","year":"1985","journal-title":"Folia Haematol Int Mag Klin Morphol Blutforsch"},{"key":"bibr30-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1592\/phco.19.4.299.30941"},{"key":"bibr31-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)93248-N"},{"key":"bibr32-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.11.1774"},{"key":"bibr33-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6075.1500"},{"key":"bibr34-aph.1G396","unstructured":"Statistics Netherlands. Unnatural death by causes, http:\/\/statline.cbs.nl\/StatWeb\/Table.asp?LA=nl&DM=SLNL&PA=37683&Dl=0-3,20-21,42-43,68,90-91,104-105,127-128&D2=0&D3=0&D4=a&STB=G1,G2,G3&HDR=T (accessed 2005 Jul 1)."},{"key":"bibr35-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.152.2.183"},{"key":"bibr36-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1176\/ps.49.8.1029"},{"key":"bibr37-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199518003-00003"},{"key":"bibr38-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.1.82"},{"key":"bibr39-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1192\/pb.25.2.46"},{"key":"bibr40-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-996-0047-6"},{"key":"bibr41-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1177\/026988110101500209"},{"issue":"3","key":"bibr42-aph.1G396","first-page":"200","volume":"59","author":"Meltzer HY","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"bibr43-aph.1G396","volume-title":"WHO resource book on mental health, human rights and legislation","year":"2005"},{"key":"bibr44-aph.1G396","volume-title":"The MacArthur Competence Assessment Tool for Clinical Research (MacCAT-CR)","author":"Appelbaum PS","year":"2001"},{"key":"bibr45-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.54.9.1247"},{"key":"bibr46-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-003-1501-3"},{"key":"bibr47-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.4.573"},{"key":"bibr48-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.52.6.780"},{"key":"bibr49-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.11.1508"},{"key":"bibr50-aph.1G396","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2004.06.009"},{"key":"bibr51-aph.1G396","doi-asserted-by":"publisher","DOI":"10.4135\/9781849209748"},{"key":"bibr52-aph.1G396","first-page":"77","volume":"7","author":"Wang PS","year":"2004","journal-title":"J Mental Health Policy Econ"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1G396","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1G396","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:12:17Z","timestamp":1777374737000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1G396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["10.1345\/aph.1G396"],"URL":"https:\/\/doi.org\/10.1345\/aph.1g396","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}